Sagopilone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 203210

CAS#: 305841-29-6

Description: Sagopilone is a fully synthetic low-molecular-weight epothilone with potential antineoplastic activity. Sagopilone binds to tubulin and induces microtubule polymerization while stabilizing microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. The agent is not a substrate for the P-glycoprotein (P-gp) efflux pump and so may exhibit activity in multidrug-resistant (MDR) tumors. The epothilone class of metabolites was originally isolated from the myxobacterium Solangium cellulosum.


Chemical Structure

img
Sagopilone
CAS# 305841-29-6

Theoretical Analysis

MedKoo Cat#: 203210
Name: Sagopilone
CAS#: 305841-29-6
Chemical Formula: C30H41NO6S
Exact Mass: 543.27
Molecular Weight: 543.710
Elemental Analysis: C, 66.27; H, 7.60; N, 2.58; O, 17.66; S, 5.90

Price and Availability

Size Price Availability Quantity
10mg USD -2
25mg USD -2
50mg USD -2
100mg USD -2
200mg USD -2
500mg USD -2
1g USD -1
2g USD -1
5g USD -1
Bulk inquiry

Synonym: ZK-Epothilone; ZK 219477; ZK-219477; ZK219477; ZK-EPO; DE 03757; DE-03757; DE03757; Sagopilone.

IUPAC/Chemical Name: (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methylbenzo[d]thiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

InChi Key: BFZKMNSQCNVFGM-UCEYFQQTSA-N

InChi Code: InChI=1S/C30H41NO6S/c1-7-9-20-27(34)17(2)10-8-13-30(6)25(37-30)15-22(19-11-12-23-21(14-19)31-18(3)38-23)36-26(33)16-24(32)29(4,5)28(20)35/h7,11-12,14,17,20,22,24-25,27,32,34H,1,8-10,13,15-16H2,2-6H3/t17-,20+,22-,24-,25-,27-,30+/m0/s1

SMILES Code: O=C(C[C@H](O)C1(C)C)O[C@H](C2=CC=C(SC(C)=N3)C3=C2)C[C@]4([H])O[C@]4(C)CCC[C@H](C)[C@H](O)[C@@H](CC=C)C1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: soluble in DMSO, not soluble in water.

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:      

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 543.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. Galmarini, Carlos M. Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Current Opinion in Investigational Drugs (BioMed Central) (2009), 10(12), 1359-1371. CODEN: COIDAZ ISSN:2040-3429. AN 2010:726309

2. Richter, Annett; Olbrich, Carsten; Krause, Michael; Hoffmann, Jens; Kissel, Thomas. Polymeric Micelles for parenteral delivery of Sagopilone: Physicochemical characterization, novel formulation approaches and their toxicity assessment in vitro as well as in vivo. European Journal of Pharmaceutics and Biopharmaceutics (2010), 75(2), 80-89. CODEN: EJPBEL ISSN:0939-6411. AN 2010:643014

3. Richter, Annett; Wiedekind, Achim; Krause, Michael; Kissel, Thomas; Haag, Rainer; Olbrich, Carsten. Non-ionic dendritic glycerol-based amphiphiles: Novel excipients for the solubilization of poorly water-soluble anticancer drug Sagopilone. European Journal of Pharmaceutical Sciences (2010), 40(1), 48-55. CODEN: EPSCED ISSN:0928-0987. CAN 153:69993 AN 2010:465236

4. Eschenbrenner, Julia. Mode of action analysis of the synthetic epothilone Sagopilone. (2009), No pp. CAN 152:397468 AN 2010:438250

5. Richter, Annett; Olbrich, Carsten; Krause, Michael; Kissel, Thomas. Solubilization of Sagopilone, a poorly water-soluble anticancer drug, using polymeric micelles for parenteral delivery. International Journal of Pharmaceutics (2010), 389(1-2), 244-253.

6. Hammer, Stefanie; Sommer, Anette; Fichtner, Iduna; Becker, Michael; Rolff, Jana; Merk, Johannes; Klar, Ulrich; Hoffmann, Jens. Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non-Small Cell Lung Cancer. Clinical Cancer Research (2010), 16(5), 1452-1465. 

7. Qi, Wenyuan; Meng, Zhiyun; Dou, Guifang. Clinical research progress of epothilone analogues. Guoji Yaoxue Yanjiu Zazhi (2009), 36(5), 336-339. CODEN: GYYZBO ISSN:1674-0440. CAN 152:559866 AN 2010:145484

8. Koitka, Matthias; Hochel, Joachim; Gieschen, Hille; Borchert, Hans-Hubert. Improving the ex vivo stability of drug ester compounds in rat and dog serum: Inhibition of the specific esterases and implications on their identity. Journal of Pharmaceutical and Biomedical Analysis (2010), 51(3), 664-678. 

9. Arnold, D.; Voigt, W.; Kiewe, P.; Behrmann, C.; Lindemann, S.; Reif, S.; Wiesinger, H.; Giurescu, M.; Thiel, E.; Schmoll, H.-J. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. British Journal of Cancer (2009), 101(8), 1241-1247.